EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

Tao Zhou, Huayun Yan, Dandan Yin, Yun Deng, Huancheng Fu, Zichen Zhao, Shuang Li, Xiaoxi Lu, Yiqi Deng, Hai-Ning Chen, Wei-Han Zhang, Yunying Shi und 10 weitere

MedComm · 2025-09 · 6 (9)

DOI: 10.1002/mco2.70361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, 2025-09. Verfasst von Tao Zhou und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine West China Hospital Sichuan University Chengdu Sichuan China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic retinoblastoma 1 ( RB1 ) loss is prevalent across different cancer types and is enriched in treatment‐refractory tumors, such as castration‐resistant prostate cancer (CRPC) and small‐cell lung cancer, but cannot be considered as a direct druggable target. In this study, we revealed that the close proximity of nudix hydrolase 15 ( NUDT15 ) and RB1 may result in their common somatic codeletion or epigenomic cosilencing in different cancer types and subsequent significant positive correlations of their expressions at the bulk transcriptional and single‐cell levels. With clinical CRPC samples, co‐loss of RB1 and NUDT15 were commonly observed (14 out of 21). Due to the contribution of NUDT15 deficiency to thiopurine‐induced toxicity, exploiting a vulnerability conferred by RB1–NUDT15 loss raised the possibility of repurposing thiopurine (e.g., mercaptopurine) for precise therapeutics. A positive relationship between RB1 / NUDT15 ploidy score and mercaptopurine drug sensitivity was found in 543 cancer cell lines. Experimentally, knocking‐down NUDT15 sensitizes the cancer cell lines to mercaptopurine treatment by inhibiting cell cycle progression and increasing apoptosis, but does not induce mercaptopurine‐related leucopenia in xenograft model. Our study elucidates the molecular basis for precise mercaptopurine therapy in RB1‐deficient tumors and demonstrates how leveraging collateral lethality alongside drug repurposing uncovers targetable vulnerabilities in stratified patient cohorts.

Schlagwörter

Stichwörter der Autor:innen

NUDT15RB1collateral lethalitycopy number deletiondrug repurposingmercaptopurine

Autor:innen und Institutionen

  • Department of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine West China Hospital Sichuan University Chengdu Sichuan China.
  • State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University Chengdu China.
  • Department of Medical Oncology Lung Cancer Center/Lung Cancer Institute West China Hospital Sichuan University Chengdu Sichuan China.
  • Department of Pathology West China Hospital Sichuan University Chengdu Sichuan China.
  • Department of Pediatric Hematology/Oncology West China Second Hospital Sichuan University Chengdu Sichuan China.
  • Department of General Surgery Colorectal Cancer Center West China Hospital Sichuan University Chengdu Sichuan China.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, T., Yan, H., Yin, D., Deng, Y., Fu, H., Zhao, Z., Li, S., Lu, X., Deng, Y., Chen, H. N., Zhang, W. H., Shi, Y., Bai, Y., Cai, B., Wang, L., Liu, Z., Zhang, W., Jiang, L., Shu, Y., …, & Xu, H. (2025). Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss. MedComm, 6(9). https://doi.org/10.1002/mco2.70361

Vancouver

Zhou T, Yan H, Yin D, Deng Y, Fu H, Zhao Z, et al. Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss. MedComm. 2025;6(9). doi:10.1002/mco2.70361

BibTeX
@article{Zhou2025,
  author = {Zhou, Tao and Yan, Huayun and Yin, Dandan and Deng, Yun and Fu, Huancheng and Zhao, Zichen and Li, Shuang and Lu, Xiaoxi and Deng, Yiqi and Chen, Hai-Ning and Zhang, Wei-Han and Shi, Yunying and Bai, Yangjuan and Cai, Bei and Wang, Lanlan and Liu, Zhaoqian and Zhang, Wei and Jiang, Lili and Shu, Yang and Liu, Bo and Zhang, Yan and Xu, Heng},
  title = {Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {9},
  doi = {10.1002/mco2.70361}
}
Kostenlos starten →